Epilepsy meets cancer: when, why, and what to do about it?

Détails

ID Serval
serval:BIB_7EEF12E369E3
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Epilepsy meets cancer: when, why, and what to do about it?
Périodique
Lancet Oncology
Auteur(s)
Weller M., Stupp R., Wick W.
ISSN
1474-5488 (Electronic)
ISSN-L
1470-2045
Statut éditorial
Publié
Date de publication
2012
Volume
13
Numéro
9
Pages
e375-e382
Langue
anglais
Notes
Publication types: Journal Article- Review sur le site éditeur et dans Wos
Résumé
The lifetime risk of having epileptic seizures is profoundly increased in patients with cancer: about 20% of all patients with systemic cancer may develop brain metastases. These patients and those with primary brain tumours have a lifetime risk of epilepsy of 20-80%. Moreover, exposure to chemotherapy or radiotherapy to the brain, cancer-related metabolic disturbances, stroke, and infection can provoke seizures. The management of epilepsy in patients with cancer includes diagnosis and treatment of the underlying cerebral pathological changes, secondary prophylaxis with antiepileptic drugs, and limiting of the effect of epilepsy and its treatment on the efficacy and tolerability of anticancer treatments, cognitive function, and quality of life. Because of the concern of drug-drug interactions, the pharmacological approach to epilepsy requires a multidisciplinary approach, specifically in a setting of rapidly increasing choices of agents both to treat cancer and cancer-associated epilepsy.
Pubmed
Web of science
Création de la notice
04/10/2012 18:07
Dernière modification de la notice
03/03/2018 18:42
Données d'usage